bioRxivGenomicsPreprint
Transcriptional signatures of progressive neuropathology in transgenic tau and amyloid mouse models.
Isabel CastanhoiD, Tracey K. Murray, Eilis J. HannoniD, Aaron R. JeffriesiD, Emma WalkeriD, Emma Laing, Hedley Baulf, Joshua HarveyiD, Andrew D. RandalliD, Karen MooreiD, Paul O’Neill, Katie LunnoniD, David Andrew CollieriD, Zeshan Ahmed, Michael J. O’Neil, Jonathan S. MilliD
Abstract
The onset and progression of Alzheimers disease (AD) is characterized by increasing intracellular aggregation of hyperphosphorylated tau protein and accumulation of {beta}-amyloid (A{beta}) in the neocortex. Despite recent success in identifying genetic risk factors for AD the transcriptional mechanisms involved in disease progression are not fully understood. We used transgenic mice harbouring human tau (rTg4510) and amyloid precursor protein (J20) mutations to investigate transcriptional changes associated with the development of both tau and amyloid pathology. Using highly-parallel RNA sequencing we profiled transcriptional variation in the entorhinal cortex at four time points identifying robust genotype-associated differences in entorhinal cortex gene expression in both models. We quantified neuropathological burden across multiple brain regions in the same individual mice, identifying widespread changes in gene expression paralleling the development of tau pathology in rTg4510 mice. Differentially expressed transcripts included genes associated with familial AD from genetic studies of human patients, and genes annotated to both common and rare variants identified in GWAS and exome-sequencing studies of late-onset sporadic AD. Systems-level analyses identified discrete co-expression networks associated with the progressive accumulation of tau, with these enriched for genes and pathways previously implicated in the neuro-immunological and neurodegenerative processes driving AD pathology. Finally, we report considerable overlap between tau-associated networks and AD-associated co-expression modules identified in the human cortex. Our data provide further support for an immune-response component in the accumulation of tau, and reveal novel molecular pathways associated with the progression of AD neuropathology.
- organism: mouse
- assay: bulk RNA-seq
- research focus: differential expression
- research focus: gene regulatory network inference
- approach: statistical model
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Methylomic signatures of tau and amyloid-beta in transgenic mouse models of Alzheimer's disease neuropathology
Szi Kay Leung, Emma Walker, … Jonathan S. Mill·npj DementiaPeer-reviewed·Apr 7, 2026
- Differential neural circuit vulnerability to β-amyloid and tau pathologies in novel Alzheimer disease mice
Maria Dolores Capilla-López, Ángel Deprada-Fernandez, … Carlos A. Saura·Molecular PsychiatryPeer-reviewed·Jan 30, 2025
- Systems genetic dissection of Alzheimer's disease brain gene expression networks
Pinghan Zhao, Omar El Fadel, … Joshua M Shulman·bioRxiv·Oct 4, 2024
- Novel Alzheimer risk genes determine the microglia response to amyloid-β but not to TAU pathology
Annerieke S. R. Sierksma, Ashley Lu, … Mark W. E. J. Fiers·EMBO Molecular MedicinePeer-reviewed·Jan 17, 2020
- Neuronal APOE4 alone is sufficient to drive tau pathology, neurodegeneration, and neuroinflammation in an Alzheimer's disease mouse model
Jessica R. Blumenfeld, Yaqiao Li, … Yadong Huang·bioRxiv·Nov 25, 2025
- Prefrontal cortex transcriptomes distinguish Alzheimers disease from asymptomatic amyloid pathology, neuropeptide loss, immune-complement activation and glial remodelling
Yusuf Aliyu Munir, Umar Sagir, … Ibrahim Maikudi Sani·bioRxiv·Nov 2, 2026